BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)

Saved in:
Bibliographic Details
Published in:Hematological oncology 2017-06, Vol.35 (S2), p.67-67
Main Authors: Chen, R., Gibb, A.L., Collins, G.P., Popat, R., El‐Sharkawi, D., Burton, C., Lewis, D., Miall, F.M., Forgie, A., Compagnoni, A., Andreola, G., Brar, S., Thall, A., Woolfson, A., Radford, J.
Format: Article
Language:English
Subjects:
Hodgkin's lymphoma
Immunotherapy
Lymphoma
Monoclonal antibodies
PD-1 protein
PD-L1 protein
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2437_54